
|Articles|February 9, 2015
Testosterone Therapy and Cardiovascular Risk
Advertisement
Dr. Abraham Morgentaler, an Associate Clinical Professor of Urology at Harvard Medical School and affiliated with Beth Israel Deaconess Medical Center, in Boston, MA, along with his coauthors, explore and clarify in the February 2015 issue of Mayo Clinic Proceedings, the value of testosterone therapy in men, and in particular the issue of cardiovascular risk.
Source:
Newsletter
Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
The UroOnc Minute: Active Surveillance for Intermediate-risk Prostate Cancer, with Michael Leapman, MD, MHS
2
The Significance of KEYNOTE-905 in Muscle-Invasive Bladder Cancer
3
Christof Vulsteke, MD, PhD, breaks down findings, implications of KEYNOTE-905
4
Chemoablation reshapes nonsurgical care in recurrent NMIBC
5




















